Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC? - Wikidata - wikimedia - TriplyDB

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

http://www.wikidata.org/entity/Q35148094

about

Tyrosine Kinase Inhibitors for the Elderly Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature Strategy for chemotherapeutic delivery using a nanosized porous metal-organic framework with a central composite design.Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a.Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.

P2860

Q26748567-8FEF1757-6463-43E1-947C-30E7CDD0A121 Q26766244-7EAD7972-FC59-4ADE-BDE2-BA3E0600EFB1 Q37670045-3B4B523B-C8E4-4347-B2E7-7E9AA99D20DA Q49787300-CBC12911-7A2C-4269-914E-3C8C51147C89 Q50079728-D75106ED-5A2B-4F4F-B752-191529A6AFE8

P2860

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

http://www.wikidata.org/entity/Q35148094

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@ast

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@en

type

label

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@ast

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@en

prefLabel

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@ast

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@en

P1433

Q35148094-AF4806B2-EF2C-4F42-9021-BAD96D651691

P1476

Q35148094-E5B50DD0-8753-48D3-AAC5-E2C9F65391EC

P2093

Q35148094-0B43AC35-8B73-4F4E-B6DD-D44DBE4D3FD4

Q35148094-12404EA1-1946-4921-BA4B-6CA260C84FF9

Q35148094-12710F04-4799-426B-B2ED-C7A3050D4B3D

Q35148094-15B0CB69-B5C5-42AF-86C7-3EE4A0499300

Q35148094-1B0A8834-FA83-4587-8B48-8456434BC4D5

Q35148094-1D065F45-DF12-489C-87F3-517479F103D9

Q35148094-314FC585-1421-4D7B-B3C5-A8BC89244E0B

Q35148094-3ED27BB4-625D-40E4-B9D3-C3E1598944A2

Q35148094-54527816-B8BF-43ED-B983-0FB56D9CFA49

Q35148094-5E8FAF54-3B83-46E1-BD78-AD0EFCA83E18

P2860

Q35148094-0F018E97-83D0-44BB-A317-A3F4A7E3AF46

Q35148094-18F4EEC2-E73B-4F4A-B306-58F5057CB010

Q35148094-1B67E1DE-B572-44ED-B578-E3EC9D56D920

Q35148094-1D395BC3-AEDF-4008-9A8C-9C89006FF8E9

Q35148094-31AA8FDB-A3F6-46D0-ADB1-61D08678FA51

Q35148094-3724F386-32F3-420C-96DA-C498648DB2CA

Q35148094-39A71B1D-4A62-4A43-B700-267C30125741

Q35148094-464BEE1D-E411-45B7-9A3A-00A0BB67FFE3

Q35148094-4AF7773F-AA29-4D6B-900D-0900D6F7F1BC

Q35148094-56841865-C74A-45FF-BFB2-9D96E6E12773

P304

Q35148094-D6AFB5A8-4FFB-4CEA-A540-6577573CE895

P31

Q35148094-D7D7D311-20DF-4E7B-96B3-402045D9F227

P356

Q35148094-CD2318EB-ED17-4A56-ACBC-C694CFFBF341

P433

Q35148094-975CA82C-9E7C-48CF-8AF6-6999BEE8024D

P478

Q35148094-27856F8C-7AD9-45A2-AB8C-B1668A50CDD8

P50

Q35148094-4C0322C0-6A97-4D64-A3F7-4E23355858D7

P577

Q35148094-5926B49D-5245-49F8-86DB-BB251DDACEC7

P5875

Q35148094-F8AEA6B7-A5E1-4495-919C-DCACB5A4729E

P698

Q35148094-3E8FB57F-5D33-4ADA-B3D4-2E6FF5CA3508

P921

Q35148094-0218835C-3DB0-48FB-AF9A-1A32CA415AA7

P932

Q35148094-B04CC592-EFA1-43A4-BACA-336BF050F2AD

P356

P1433

Journal of Cancer

P1476

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

@en

P2093

Alexandra Liaka

http://www.w3.org/2001/XMLSchema#string

Dimitrios Bougiouklis

http://www.w3.org/2001/XMLSchema#string

Ellada Eleutheriadou

http://www.w3.org/2001/XMLSchema#string

George Kyriazis

http://www.w3.org/2001/XMLSchema#string

George Lazaridis

http://www.w3.org/2001/XMLSchema#string

Georgia Trakada

http://www.w3.org/2001/XMLSchema#string

John Organtzis

http://www.w3.org/2001/XMLSchema#string

Kaid Darwiche

http://www.w3.org/2001/XMLSchema#string

Kalliopi Domvri

http://www.w3.org/2001/XMLSchema#string

Katerina Tsirgogianni

http://www.w3.org/2001/XMLSchema#string

P2860

Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.

A review of first-line treatment for small-cell lung cancer.

Somatostatin and cancer: applying endocrinology to oncology.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice.

A case of typical pulmonary carcinoid tumor treated with bronchoscopic therapy followed by lobectomy.

P304

360-366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.11308

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Vasilis Karavasilis

P577

2015-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273631488

http://www.w3.org/2001/XMLSchema#string

P698

25767606

http://www.w3.org/2001/XMLSchema#string

P921

P932

4349876

http://www.w3.org/2001/XMLSchema#string